drug. (G) The number of similarly effective prescription drugs or alternative treatment regimens for each approved use of such prescription drug. (H) Whether the prescription drug provided a significant improvement in health outcomes, compared to other therapies available at the time of its approval, as determined through clinical effectiveness. (I) The current wholesale acquisition cost of comparable prescription drugs in the United States, to the extent that those prices have been deemed appropriate. (J) The cumulative and expected global revenue generated by the prescription drug. (K) The price of the drug in other countries, including in the prescription drug reference countries. (L) The public health benefit of the drug. (M) The information that the manufacturer submits to the Bureau as required under this section. (N) Any other information, as the Bureau requires. (2) Special rules (A) Interim appropriate price of prescription drugs (i) In general For each prescription drug described in clause (ii), the Bureau shall— (I) establish an interim appropriate price, which shall be the lesser of— (aa) the median list price of the prescription drug in the prescription drug reference countries